Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Current Deferred Revenue: 2017-2025

Historic Current Deferred Revenue for RedHill Biopharma (RDHL) over the last 6 years, with Jun 2025 value amounting to $10.5 million.

  • RedHill Biopharma's Current Deferred Revenue rose 486.59% to $10.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $10.5 million, marking a year-over-year increase of 486.59%. This contributed to the annual value of $9.3 million for FY2024, which is 12.82% down from last year.
  • Latest data reveals that RedHill Biopharma reported Current Deferred Revenue of $10.5 million as of Q2 2025, which was up 13.49% from $9.3 million recorded in Q4 2024.
  • RedHill Biopharma's 5-year Current Deferred Revenue high stood at $47.9 million for Q4 2022, and its period low was -$31.5 million during Q2 2023.
  • Moreover, its 3-year median value for Current Deferred Revenue was $9.9 million (2024), whereas its average is $4.5 million.
  • Over the last 5 years, RedHill Biopharma's Current Deferred Revenue had its largest YoY gain of 3,724.30% in 2023, and its largest YoY loss of 469.90% in 2023.
  • Quarterly analysis of 5 years shows RedHill Biopharma's Current Deferred Revenue stood at $30.7 million in 2021, then skyrocketed by 55.87% to $47.9 million in 2022, then slumped by 77.74% to $10.7 million in 2023, then fell by 12.82% to $9.3 million in 2024, then spiked by 486.59% to $10.5 million in 2025.
  • Its last three reported values are $10.5 million in Q2 2025, $9.3 million for Q4 2024, and $1.8 million during Q2 2024.